...
首页> 外文期刊>Helicobacter >Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication: A systematic review and meta-analysis with trial sequential analysis
【24h】

Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication: A systematic review and meta-analysis with trial sequential analysis

机译:Saccharomyces Boulardii作为幽门螺杆菌根除幽门螺杆菌的辅助治疗:具有试验顺序分析的系统评价和荟萃分析

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background and Aims Whether Saccharomyces boulardii (S boulardii) as an adjuvant therapy are beneficial to H pylori eradication remains controversial. The aim of the study was to update and determine the effects of S boulardii as an adjuvant therapy on H pylori eradication rates and adverse effects. Methods We searched PubMed, Embase, CENTRAL, and Web of Science to collect all randomized controlled trials assessing the effects of S boulardii as an adjuvant therapy for H pylori eradication from inception to February 2019. Quality of evidence was appraised using Grading of Recommendations, Assessment, Development and Evaluation system. Trial sequential analysis was performed to control the risk of type I and type II errors. Results Eighteen trials with 3592 patients were eligible for meta-analysis. Compared with standard eradication regimen, the S boulardii supplementation could significantly improve eradication rates [risk ratio (RR) = 1.09, 95% confidence interval (CI):1.05-1.13; moderate quality evidence] and reduce the incidence of total side effects (RR = 0.47, 95%CI:0.36-0.61; low quality evidence), as well as some gastrointestinal adverse effects, especially diarrhea (RR = 0.33, 95%CI:0.23-0.47; low quality evidence) and constipation (RR = 0.37, 95%CI:0.23-0.57; moderate quality evidence). In addition, the need for discontinuation rate in S boulardii supplementation group was significantly lower than in the control group (RR = 0.33, 95%CI:0.16-0.69, P = .003; moderate quality evidence). The TSA results for overall eradication rates and total side effects indicated that the effects were conclusive. Conclusions Our meta-analysis shows that S boulardii supplementation on standard eradication therapy significantly increased H pylori eradication rates and reduced the incidence of total side effects and some gastrointestinal adverse effects during eradication therapy.
机译:背景和旨在糖酵母是否有益于H幽门螺杆菌的酵母菌遗骸仍然存在争议。该研究的目的是更新并确定S Boulardii作为H幽门螺杆菌根除率和不良反应的辅助治疗的影响。方法搜索科学,Embase,Central和Web,收集所有随机对照试验,评估S Boulardii作为H Pylori灭绝的辅助治疗从成立于2019年2月的辅助治疗。使用建议评估评估证据质量,评估,发展和评估系统。进行试验顺序分析以控制I型和II型错误的风险。结果3592名患者的88名试验有资格进行荟萃分析。与标准根除方案相比,S Boulardii补充可以显着提高消除率[风险比(RR)= 1.09,95%置信区间(CI):1.05-1.13;质量适度的证据,减少总副作用的发生率(RR = 0.47,95%CI:0.36-0.61;低质量证据),以及一些胃肠道不良影响,尤其是腹泻(RR = 0.33,95%CI:0.23 -0.47;低质量证据)和便秘(RR = 0.37,95%CI:0.23-0.57;适度的质量证据)。此外,在SBoulardii补充组中停用率的需求显着低于对照组(RR = 0.33,95%CI:0.16-0.69,P = .003;中等质量证据)。 TSA的整体根除率和总副作用的结果表明,这些效果是确凿的。结论我们的荟萃分析表明,S Boulardii对标准根除治疗的补充显着增加了H幽门螺杆菌根除率,并降低了根除治疗期间的总副作用和一些胃肠不良反应的发病率。

著录项

  • 来源
    《Helicobacter》 |2019年第5期|共16页
  • 作者单位

    China Three Gorges Univ Peoples Hosp Peoples Hosp Yichang 1 Dept Gastroenterol Yichang Hubei Peoples R China;

    Univ Sydney Fac Med &

    Hlth Sydney Med Sch Kolling Inst Inst Bone &

    Joint Res Sydney NSW Australia;

    Capital Med Univ Beijing Inst Tradit Chinese Med Beijing Hosp Tradit Chinese Med Beijing Peoples R China;

    China Three Gorges Univ Peoples Hosp Peoples Hosp Yichang 1 Dept Gastroenterol Yichang Hubei Peoples R China;

    China Three Gorges Univ Peoples Hosp Peoples Hosp Yichang 1 Dept Gastroenterol Yichang Hubei Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 微生物学;
  • 关键词

    Helicobacter pylori; meta-analysis; Saccharomyces boulardii; trial sequential analysis;

    机译:幽门螺杆菌;Meta分析;糖酵母Boulardii;试验顺序分析;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号